Gilead set to open $250m, 23-acre campus
pharmafile | August 15, 2017 | News story | Manufacturing and Production | Gilead, biotech, drugs, pharma, pharmaceutical
Gilead is set for the grand unveiling of its new facility in La Verne, Southern California, after several years of work. The facility, once it is running at full capacity, is it to create jobs for 500 workers.
The campus will initially focus on the manufacture of AmBisome, an antifungal medication that is used to combat fungal infections and a form of meningitis in people carrying HIV. As well as this, the campus will have the capacity to package, label and distribute other treatments owned by the company, including its hepatitis C treatments.
“Up to 14 million tablets will be packaged and up to 5 million AmBisome vials will be manufactured per year,” company spokesman Michele Rest was reported as saying to San Gabriel Valley Tribune. “Employee numbers in La Verne will increase as we build to full commercial operation.”
The majority of the campus is made up of one 320,000-square-foot building – that is actually made of five-interconnected buildings – but there is potential for further development in an 80,000-square-foot space.
The space will replace an existing manufacturing plant that is currently located in Sam Dimas. The two cities are direct neighbours, only three miles apart, meaning that current employees will not have to relocate to begin working at the new facility.
The new La Verne site will join two other California-based operations for the giant biotech, which also possesses operations in Oceanside and Fremont.
The ceremony to open the facility is expected to take place tomorrow and will be attended by CEO, John F. Milligan.
Ben Hargreaves
Related Content
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …
